Skip to content
ChickenStockChickenStock
ResearchRYTM
Rhythm Pharmaceuticals logo

Rhythm Pharmaceuticals (RYTM) stock

NASDAQ

$115.15+4.82%(+5.30)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-41.15x

Net loss — not comparable

P/B

90.72x

P/S

28.51x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 80.4% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 3, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

26 SEC filings
  • Meeker David PPresident and CEO · Sep 14, 2026Open-market sale50,000 shares · $5.1M
    Avg. price $102.6688
    Show 5 price lots
    • 30,746 shares × $102.347$3.1M
    • 8,698 shares × $103.43$900K
    • 6,439 shares × $101.7464$655K
    • 2,300 shares × $105.19$242K
    • 1,817 shares × $104.5487$190K
  • Meeker David PPresident and CEO · Sep 14, 2026Option exercise50,000 shares · $303K
    Avg. price $6.05289,258 shares held after
  • Smith Hunter CChief Financial Officer · Aug 31, 2026Open-market sale62,774 shares · $6.6M
    Avg. price $105.4563
    Show 3 price lots
    • 28,188 shares × $106.2029$3.0M
    • 23,072 shares × $104.5871$2.4M
    • 11,514 shares × $105.3702$1.2M
  • Smith Hunter CChief Financial Officer · Aug 31, 2026Option exercise57,187 shares · $1.5M
    Avg. price $25.79176,798 shares held after
  • Lee Jennifer KaydenEVP, Head of North America · Aug 13, 2026Open-market sale75,834 shares · $8.9M
    Avg. price $117.38180 shares held after
  • Shulman JosephChief Technical Officer · Aug 13, 2026Open-market sale5,079 shares · $608K
    Avg. price $119.7515,915 shares held after
  • Garfield AlastairChief Scientific Officer · Aug 13, 2026Open-market sale7,763 shares · $913K
    Avg. price $117.5709
    Show 4 price lots
    • 3,400 shares × $118.2843$402K
    • 2,007 shares × $116.1093$233K
    • 1,556 shares × $117.0759$182K
    • 800 shares × $119.1688$95K
  • Lee Jennifer KaydenEVP, Head of North America · Aug 13, 2026Option exercise56,601 shares · $997K
    Avg. price $17.6152
    Show 2 price lots
    • 35,000 shares × $24.29$850K
    • 21,601 shares × $6.8$147K
  • Shulman JosephChief Technical Officer · Aug 13, 2026Option exercise2,024 shares · $14K
    Avg. price $6.820,994 shares held after
  • Mazabraud YannEVP, Head of International · Aug 12, 2026Open-market sale57,000 shares · $6.6M
    Avg. price $116.1504
    Show 6 price lots
    • 18,208 shares × $116.4941$2.1M
    • 17,319 shares × $117.4686$2.0M
    • 14,568 shares × $115.427$1.7M
    • 3,605 shares × $114.6955$413K
    • 2,300 shares × $111.7992$257K
    • 1,000 shares × $112.856$113K
  • Mazabraud YannEVP, Head of International · Aug 12, 2026Option exercise46,625 shares · $317K
    Avg. price $6.8112,655 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Rhythm Pharmaceuticals (RYTM) stock information

NASDAQ

Rhythm Pharmaceuticals (RYTM) is listed on NASDAQ. Its market capitalization is about $8B. On trailing-twelve-month earnings the P/E ratio is -41.15, and the P/B ratio is 90.72. Return on equity is -220.5%. These figures are computed in-house from official filings and are reference information only.

Rhythm Pharmaceuticals — frequently asked questions

What is the P/E ratio of Rhythm Pharmaceuticals (RYTM)?
On a trailing-twelve-month basis, RYTM trades at a P/E ratio of -41.15. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Rhythm Pharmaceuticals?
RYTM has a market capitalization of about $8B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.